Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017 MannKind Names Lilly Exec as New CMO February 5, 2018 Iovance Biotherapeutics Partners With TrakCel For Personalized Patient Product Management September 10, 2017
AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer May 7, 2017
Iovance Biotherapeutics Partners With TrakCel For Personalized Patient Product Management September 10, 2017
